NEW YORK, Sept. 13, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it will be initiating a groundbreaking in-human clinical study to treat people who suffer from diabetic induced critical limb ischemia wounds. IntelliCell has developed a proprietary treatment methodology using its autologous (your own) cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. According to the American Diabetes Association, there are "over 65,000 lower limb amputations performed in the United States" as a direct consequence of diabetes and hundreds of thousands of diabetes related amputations globally.

Dr. Steven Victor, Chairman and CEO of IntelliCell stated, "Diabetes is a growing problem in the United States and around the world. We hope to show that our unique autologous cellular therapy may make a contribution to those who suffer from this terrible disease and reduce the number of people that undergo amputations from non-healing wounds in their legs and other extremities."

Robert Sexauer, VP of Clinical Development added, "Regenerative Medicine is progressing to the point whereby we can begin to truly offer personalized medicine based on each patients unique needs. IntelliCell has developed a novel treatment methodology that may impact a number of disease states with significant unmet clinical needs

(0)

(0)

Investors Hangout

Whats Hot